Advertisement

Celltrion

Share

Celltrion deepens bet on US biotech Kaigene with 3rd autoimmune drug candidate Korea Biomedical Review 05:38 Thu, 22 Oct

Korea Biomedical Review 05:38 Thu, 22 Oct

Pharma Biotechnology

Celltrion secures three autoimmune drug candidates through deal with U.S. firm Kaigene Asia Today 07:20 Thu, 22 Oct

Asia Today 07:20 Thu, 22 Oct

Pharma Biotechnology

Celltrion's Omlyclo, Avtozma displace originators in US formulary deals Korea Biomedical Review 00:41 Mon, 26 Oct

Korea Biomedical Review 00:41 Mon, 26 Oct

Advertisement

Advertisement

Celltrion's 4-hormone obesity drug beats Lilly's retatrutide on weight loss in rat study Korea Biomedical Review 5d

Korea Biomedical Review 5d

Celltrion and Kaigene sign $580m licence deal for KG013 Hospital Management 10:44 Fri, 23 Oct

Hospital Management 10:44 Fri, 23 Oct

Mergers and Acquisitions Biotechnology

FTC fines Celltrion 630 million won over unfair test kit subcontracting Korea JoongAng Daily 05:11 Thu, 29 Oct

Korea JoongAng Daily 05:11 Thu, 29 Oct

Advertisement

Advertisement

Latest

Friday

Celltrion nears annual target on biosimilar surge Korea JoongAng Daily 00:07 Fri, 06 Nov

Thursday

Celltrion brings 3 new biosimilars to Brazil, taking portfolio to 10 Korea Biomedical Review 02:16 Thu, 05 Nov

Wednesday

Celltrion unveils promising results for four-target obesity drug The Korea Herald 05:06 Wed, 04 Nov

Celltrion's 4-hormone obesity drug beats Lilly's retatrutide on weight loss in rat study Korea Biomedical Review 01:06 Wed, 04 Nov

Monday

Celltrion Pharm adds lower-priced safety syringe to Yuflyma lineup Korea Biomedical Review 07:27 Mon, 02 Nov

In the last month

FTC fines Celltrion 630 million won over unfair test kit subcontracting Korea JoongAng Daily 05:11 Thu, 29 Oct

Watchdog to fine Celltrion 630m over unfair subcontracting practices The Korea Herald 05:00 Thu, 29 Oct

Watchdog to fine Celltrion $469,000 over unfair subcontracting practices The Korea Times 03:44 Thu, 29 Oct

Celltrion Q3 operating profit jumps 74% on strong sales of high-margin biosimilars Korea Biomedical Review 01:06 Tue, 27 Oct

Celltrion's Omlyclo, Avtozma displace originators in US formulary deals Korea Biomedical Review 00:41 Mon, 26 Oct

Advertisement

Advertisement

Advertisement

My Local News

Advertisement

About our Celltrion news

Latest news on Celltrion, a biopharmaceutical company headquartered in Incheon, South Korea.